.gamma.-brain natriuretic peptide
Also known as: BNP C-terminal fragment, gamma-BNP, γ-BNP
Summary
Gamma-brain natriuretic peptide (γ-BNP) is a C-terminal fragment of BNP(1-32) generated by enzymatic cleavage, primarily by neprilysin and other endopeptidases. It is considered biologically inactive or has markedly reduced natriuretic/vasoactive activity compared to the parent BNP molecule. It is used primarily as a research tool to study BNP metabolism and as a biomarker fragment in cardiovascular research.
Mechanism of Action
Binds to natriuretic peptide receptors (NPR-A/NPR-B), activating guanylate cyclase to increase intracellular cGMP, leading to vasodilation, natriuresis, diuresis, and inhibition of the renin-angiotensin-aldosterone system (RAAS). Gamma-BNP is a degradation fragment of BNP with reduced or absent receptor activation compared to the full-length BNP molecule.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- Biomarker research for heart failureResearch/DiagnosticLow
- Understanding BNP metabolismResearchModerate
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
- European UnionUnapprovedNo approved therapeutic or diagnostic use; research reagent only
- United StatesUnapprovedNo approved therapeutic or diagnostic use; research reagent only
- United KingdomUnapprovedNo approved therapeutic or diagnostic use; research reagent only
Not approved by any regulatory agency for therapeutic use. Exists only as a research reagent and metabolic degradation product studied in the context of heart failure biomarker research.
Evidence & Sources
No sources recorded yet.